Compounds Useful for Multi-Level Specific Targeting of Cancer Cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 13/086,698, filed Apr 14, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,771,404 | Multi-Level Specific Targeting of Cancer Cells In force · Medium confidence | Wake Forest University Health Sciences | In force | Medium confidence | ||
| US 10,233,224 | Nucleic Acids Encoding a Fusion Protein Useful for Multi-Level Specific Targeting of Cancer Cells In force · Medium confidence | Wake Forest University Health Sciences | In force | Medium confidence | ||
| US 10,519,210 | Multi-Level Specific Targeting of Cancer Cells In force · Medium confidence | Wake Forest University Health Sciences | In force | Medium confidence | ||
| US 11,136,367 | Multi-Level Specific Targeting of Cancer Cells In force · Medium confidence | Wake Forest University Health Sciences | In force | Medium confidence | ||
| US 9,005,600 | Compounds Useful for Multi-Level Specific Targeting of Cancer Cells In force · Low confidence | Wake Forest University Health Sciences | In force | Low confidence | ||
| US 11,976,101 | Multi-Level Specific Targeting of Cancer Cells In force · Low confidence | Wake Forest University Health Sciences | In force | Low confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.